Coagulation factor VII variants resistant to inhibitory antibodies

Thrombosis and Haemostasis

Volumn 112, Issue 5, 2014, Pages 972-980

  Branchini, Alessio ^a   Baroni, Marcello ^a   Pfeiffer, Caroline ^b,c   Batorova, Angelika ^d   Giansily Blaizot, Muriel ^b   Schved, Jean F ^b   Mariani, Guglielmo ^a   Bernardi, Francesco ^a   Pinotti, Mirko ^a  

^a UNIVERSITY OF FERRARA   (Italy)

^b MONTPELLIER UNIVERSITY HOSPITAL   (France)

^c CNRS   (France)

^d UNIVERSITY HOSPITAL BRATISLAVA   (Slovakia)

Author keywords

Carboxyl terminus; Factor VII deficiency; Inhibitory antibodies; Recombinant proteins; Replacement therapy

Indexed keywords

ANTIBODY; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 7; IMMUNOGLOBULIN CLASS; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2; IMMUNOGLOBULIN G3; IMMUNOGLOBULIN G4; INHIBITORY ANTIBODY; RECOMBINANT BLOOD CLOTTING FACTOR 7A; THROMBIN; UNCLASSIFIED DRUG; ALLOANTIBODY; BLOOD CLOTTING FACTOR 7A; IMMUNOGLOBULIN G; RECOMBINANT FVIIA; RECOMBINANT PROTEIN;

ANTIBODY AFFINITY; ANTIGEN BINDING; ARTICLE; BINDING ASSAY; BLOOD CLOTTING; BLOOD CLOTTING FACTOR 7 DEFICIENCY; BLOOD SAMPLING; CONTROLLED STUDY; FLUORESCENCE; GENETIC VARIABILITY; HOMOZYGOTE; HUMAN; IMMUNE RESPONSE; KINETICS; MUTATION; PROTEIN EXPRESSION; THROMBIN TIME; AMINO ACID SEQUENCE; ANTAGONISTS AND INHIBITORS; ANTIGEN ANTIBODY REACTION; BIOSYNTHESIS; CHEMISTRY; FACTOR VII DEFICIENCY; FRAMESHIFT MUTATION; GENE DELETION; GENETICS; IMMUNOLOGY; MOLECULAR GENETICS; PROTEIN ANALYSIS; PROTEIN TERTIARY STRUCTURE; STRUCTURE ACTIVITY RELATION;

AMINO ACID SEQUENCE; ANTIGEN-ANTIBODY REACTIONS; BLOOD COAGULATION; FACTOR VII; FACTOR VII DEFICIENCY; FACTOR VIIA; FACTOR XA; FRAMESHIFT MUTATION; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULIN ISOTYPES; ISOANTIBODIES; MOLECULAR SEQUENCE DATA; PROTEIN INTERACTION MAPPING; PROTEIN STRUCTURE, TERTIARY; RECOMBINANT PROTEINS; SEQUENCE DELETION; STRUCTURE-ACTIVITY RELATIONSHIP; THROMBIN;

EID: 84908541961     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH14-03-0198     Document Type: Article

References (41)

1. Kreuz W, Becker S, Lenz E, et al. Factor VIII inhibitors in patients with haemophilia A: epidemiology of inhibitor development and induction of immune tolerance for factor VIII. Semin Thromb Haemost 1995; 21: 382-389.
2. DiMichele D. Inhibitor development in haemophilia B: an orphan disease in need of attention. Br J Haematol 2007; 138: 305-315.
3. Mariani G, Konkle B, Kessler CM. Inhibitors in Haemophilia A and B. In: Hematology: Basic Principles and Practice, 6th edn. Philadelphia, PA: Elsevier Saunders, 2012: pp. 1961-1970.
4. Gouw SC, van den Berg HM, Oldenburg J, et al. F8 gene mutation type and inhibitor development in patients with severe haemophilia A: systematic review and meta-analysis. Blood 2012; 119: 2922-2934.
5. Gouw SC, van den Berg HM, le Cessie S, et al. Treatment characteristics and the risk of inhibitor development: a multicenter cohort study among previously untreated patients with severe haemophilia A. J Thromb Haemost 2007; 5: 1383-1390.
6. Ingerslev J, Christiansen K, Sorensen B, International Registry on Factor VIIDSC. Inhibitor to factor VII in severe factor VII deficiency: detection and course of the inhibitory response. J Thromb Haemost 2005; 3: 799-800.
7. Pruthi RK, Rodriguez V, Allen C, et al. Molecular analysis in a patient with severe factor VII deficiency and an inhibitor: report of a novel mutation (S103G). Eur J Haematol 2007; 79: 354-359.
8. Tokgoz H, Caliskan U, Lavigne-Lissalde G, et al. Successful prophylactic use of recombinant activated factor VII (rFVIIa) in a patient with congenital FVII deficiency and inhibitors to FVII. Haemophilia 2012; 18: e25-27.
9. Batorova A, Mariani G, Kavakli K, et al., on behalf of the STER Study Group. Inhibitors to factor VII and in congenital factor VII deficiency. Haemophilia 2014; 20: e188-191.
10. Greer J. Comparative modeling methods: application to the family of the mammalian serine proteases. Proteins 1990; 7: 317-334.
11. Furie B, Furie BC. Molecular and cellular biology of blood coagulation. N Engl J Med 1992; 326: 800-806.
12. Mariani G, Herrmann FH, Dolce A, et al., International Factor VIIDSG. Clinical phenotypes and factor VII genotype in congenital factor VII deficiency. Thromb Haemost 2005; 93: 481-487.
13. Rosen ED, Chan JC, Idusogie E, et al. Mice lacking factor VII develop normally but suffer fatal perinatal bleeding. Nature 1997; 390: 290-294.
14. Hay CR, Ollier W, Pepper L, et al. HLA class II profile: a weak determinant of factor VIII inhibitor development in severe haemophilia A. UKHCDO Inhibitor Working Party. Thromb Haemost 1997; 77: 234-237.
15. Oldenburg J, Pavlova A. Genetic risk factors for inhibitors to factors VIII and IX. Haemophilia 2006; 12 (Suppl 6): 15-22.
16. Astermark J, Donfield SM, Gomperts ED, et al., Haemophilia Inhibitor Genetics Study Combined C. The polygenic nature of inhibitors in haemophilia A: results from the Haemophilia Inhibitor Genetics Study (HIGS) Combined Cohort. Blood 2013; 121: 1446-1454.
17. Pavlova A, Delev D, Lacroix-Desmazes S, et al. Impact of polymorphisms of the major histocompatibility complex class II, interleukin-10, tumor necrosis factor-alpha and cytotoxic T-lymphocyte antigen-4 genes on inhibitor development in severe haemophilia A. J Thromb Haemost 2009; 7: 2006-2015.
18. Bowen DJ. Haemophilia A and haemophilia B: molecular insights. Mol Pathol 2002; 55: 1-18.
19. Schwaab R, Pavlova A, Albert T, et al. Significance of F8 missense mutations with respect to inhibitor formation. Thromb Haemost 2013; 109: 464-470.
20. Sharathkumar A, Lillicrap D, Blanchette VS, et al. Intensive exposure to factor VIII is a risk factor for inhibitor development in mild haemophilia A. J Thromb Haemost 2003; 1: 1228-1236.
21. Arbini AA, Bodkin D, Lopaciuk S, et al. Molecular analysis of Polish patients with factor VII deficiency. Blood 1994; 84: 2214-2220.
22. Wulff K, Herrmann FH. Twenty two novel mutations of the factor VII gene in factor VII deficiency. Hum Mutat 2000; 15: 489-496.
23. Giles AR, Verbruggen B, Rivard GE, et al. A detailed comparison of the performance of the standard versus the Nijmegen modification of the Bethesda assay in detecting factor VIII: C inhibitors in the haemophilia A population of Canada. Association of Haemophilia Centre Directors of Canada. Factor VIII/IX Subcommittee of Scientific and Standardisation Committee of International Society on Thrombosis and Haemostasis. Thromb Haemost 1998; 79: 872-875.
24. Branchini A, Rizzotto L, Mariani G, et al. Natural and engineered carboxy-terminal variants: decreased secretion and gain-of-function result in asymptomatic coagulation factor VII deficiency. Haematologica 2012; 97: 705-709.
25. Baroni M, Mazzola G, Kaabache T, et al. Molecular bases of type II protein S deficiency: the I203-D204 deletion in the EGF4 domain alters GLA domain function. J Thromb Haemost 2006; 4: 186-191.
26. Lavigne-Lissalde G, Rothschild C, Pouplard C, et al. Characteristics, mechanisms of action, and epitope mapping of anti-factor VIII antibodies. Clin Rev Allergy Immunol 2009; 37: 67-79.
27. Miller CH, Platt SJ, Rice AS, et al., Haemophilia Inhibitor Research Study I. Validation of Nijmegen-Bethesda assay modifications to allow inhibitor measure-ment during replacement therapy and facilitate inhibitor surveillance. J Thromb Haemost 2012; 10: 1055-1061.
28. Al Dieri R, Peyvandi F, Santagostino E, et al. The thrombogram in rare inherited coagulation disorders: its relation to clinical bleeding. Thromb Haemost 2002; 88: 576-582.
29. Castoldi E, Rosing J. Thrombin generation tests. Thromb Res 2011; 127 (Suppl 3): S21-25.
30. Olivieri O, Martinelli N, Baroni M, et al. Factor II activity is similarly increased in patients with elevated apolipoprotein CIII and in carriers of the factor II 20210A allele. J Am Heart Assoc 2013; 2: e000440.
31. Reding MT. Immunological aspects of inhibitor development. Haemophilia 2006; 12 Suppl 6: 30-36.
32. van Helden PM, van den Berg HM, Gouw SC, et al. IgG subclasses of anti-FVIII antibodies during immune tolerance induction in patients with haemophilia A. Br Journal Haematol 2008; 142: 644-652.
33. Eigenbrot C, Kirchhofer D, Dennis MS, et al. The factor VII zymogen structure reveals reregistration of beta strands during activation. Structure. 2001; 9: 627-636.
34. Larsen KS, Østergaard H, Bjelke JR, et al. Engineering the substrate and inhibitor specificities of human coagulation Factor VIIa. Biochem J 2007; 405: 429-438.
35. Gray LD, Hussey MA, Larson BM, et al. Recombinant factor VIIa analog NN1731 (V158D/E296V/M298Q-FVIIa) enhances fibrin formation, structure and stability in lipidated haemophilic plasma. Thromb Res 2011; 128: 570-576.
36. Weimer T, Wormsbacher W, Kronthaler U, et al. Prolonged in-vivo half-life of factor VIIa by fusion to albumin. Thromb Haemost 2008; 99: 659-667.
37. Persson E, Bolt G, Steenstrup TD, et al. Recombinant coagulation factor VIIa-from molecular to clinical aspects of a versatile haemostatic agent. Thromb Res 2010; 125: 483-489.
38. Collins PW. Treatment of acquired haemophilia A. J Thromb Haemost 2007; 5: 893-900.
39. Abshire T, Kenet G. Recombinant factor VIIa: review of efficacy, dosing regimens and safety in patients with congenital and acquired factor VIII or IX inhibitors. J Thromb Haemost 2004; 2: 899-909.
40. James EA, van Haren SD, Ettinger RA, et al. T-cell responses in two unrelated haemophilia A inhibitor subjects include an epitope at the factor VIII R593C missense site. J Thromb Haemost 2011; 9: 689-699.
41. Eckhardt CL, Menke LA, van Ommen CH, et al. Intensive peri-operative use of factor VIII and the Arg593->Cys mutation are risk factors for inhibitor development in mild/moderate haemophilia A. J Thromb Haemost 2009; 7: 930-937.